HDSA Accepting Letters of Interest for 2020 Centers of Excellence Program
Posted on August 15, 2019
HDSA’s Centers of Excellence (COEs) provide multidisciplinary care services to families affected by Huntington’s disease, including neurology, psychology, genetic counseling,…
Read MoreParticipate in HDSA’s Survey About PGD-IVF
Posted on August 8, 2019
HDSA is committed to providing individuals and families impacted by HD with the resources they need to make informed choices….
Read MorePRECISION-HD2 Results from Wave Life Sciences Expected in Late 2019
Posted on August 1, 2019
Wave Life Sciences is conducting two early safety studies of huntingtin-lowering therapies, called PRECISION-HD1 and PRECISION-HD2. In a business update…
Read MoreHD Legacy: Brain Donation for HD Research
Posted on July 25, 2019
To enable cutting-edge Huntington’s disease research, HDSA is collaborating with CHDI to support the donation of brain and other organs…
Read MoreGene Silencing Therapy for Amyloidosis Approved in the UK
Posted on July 17, 2019
Last week saw the approval of a genetic therapy for a rare disease called hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). As…
Read MoreThe Blog Returns: 34th Annual HDSA Convention Research Recap
Posted on July 11, 2019
This week, Dr. Fox returns from maternity leave and resumes the HDSA research blog! The 34th Annual HDSA Convention in…
Read More#LetsTalkAboutHD
Posted on April 4, 2019
May is HD awareness month, and every day HDSA will be sharing family stories, celebrity PSAs, HD facts and much…
Read MoreRoche/Genentech Amends GENERATION-HD1 Study
Posted on March 28, 2019
On Thursday, March 21st, Roche/Genentech released a Community Statement about changes to the GENERATION-HD1 study, the clinical trial testing huntingtin-lowering…
Read MoreInterview with Roche Representatives
Posted on March 21, 2019
A few weeks ago we blogged about the Annual CHDI Huntington’s disease Therapeutics Conference in Palm Springs, California. This week,…
Read MoreGene Therapy 101
Posted on March 14, 2019
In addition to ongoing clinical trials of Roche/Genentech and Wave huntingtin-lowering therapies, a number of other companies are developing drugs…
Read MoreAnnual CHDI Huntington’s Disease Therapeutics Conference
Posted on March 7, 2019
This week in Palm Springs, California, CHDI Foundation hosted the 14th Annual HD Therapeutics Conference. This yearly conference draws academic…
Read MoreSecond Annual HD-COPE Meeting
Posted on February 28, 2019
The Huntington’s Disease Coalition for Patient Engagement (HD-COPE) met this week in New York City. HD-COPE unites organizations serving HD…
Read MoreHDSA Research Webinar on DNA Repair Next Thursday, February 20th
Posted on February 14, 2019
Over the past 15-20 years we have learned that the CAG repeat mutation that causes HD is dynamic – the…
Read MoreHDSA Expands Centers of Excellence Program to 47 Sites
Posted on February 7, 2019
HDSA Centers of Excellence provide world-class multidisciplinary care to families all over the United States. Professionals at these locations include…
Read MoreFirst Patient Enrolled in Pivotal Huntingtin-Lowering Trial
Posted on January 31, 2019
This week, Ionis Pharmaceuticals issued a press release stating that the Phase 3 trial of the huntingtin-lowering therapy formerly known…
Read MoreTwo Announcements From Drug Companies
Posted on January 24, 2019
This week, we learned that the SIGNAL trial has completed recruitment for its Phase 2 study of VX15/2503 (pepinemab), a…
Read More2018 Research Year In Review Webinar Available
Posted on January 17, 2019
If you weren’t able to join us for the 2018 HD Research Year-in-Review webinar or would like to have another…
Read MoreAmerican Society of Human Genetics Chooses Huntington’s Disease as Topic for 2019 Essay Contest
Posted on January 10, 2019
The American Society of Human Genetics (ASHG) is a nonprofit organization whose mission is to advance human genetics in science,…
Read More2018 Research Year in Review Webinar
Posted on January 3, 2019
To complement our 2018 Research Report, George and Leora will be sharing this year’s HD research highlights in our 2018…
Read MoreRoche/Genentech Announces Locations of GENERATION HD1 Drug Study
Posted on December 20, 2018
On Wednesday, December 19th, Roche/Genentech announced the US and Canadian locations for their upcoming study to test efficacy of the huntingtin-lowering…
Read More